ArticleNature communications2020
c-Myc inactivation of p53 through the pan-cancer lncRNA MILIP drives cancer pathogenesis.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
6.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 125 citations in OpenAlex.
- Anthocyanin Derived NIR Fluorogenic Probe for Direct Visualization and Monitoring of DNA G‑Quadruplex in Breast Cancer Tumor Models.Chemical & biomedical imaging · 2026Article
- The MAFG-AS1/G6PD axis reduces platinum sensitivity in colorectal cancer through pentose phosphate pathway activation.Journal of translational medicine · 2026Article
- lncRNA AL445238.2‑USP4 axis regulates cell survival and stemness in colon cancer.International journal of oncology · 2026Article
- Myc-mediated epigenetic silencing of ACAP3 promotes lung adenocarcinoma proliferation via regulating EGFR dynamics.British journal of cancer · 2026Article
- Mechanism of N6-methyladenosine (m6A)-mediated upregulation of LINC00958 in the growth of cervical cancer.Frontiers in oncology · 2026Article
- An exploratory study on the potential of angiogenic genes in early HNSCC detection.Discover oncology · 2025Article
- Novel insights into lncRNAs as key regulators of post-translational modifications in cancer: mechanisms and therapeutic potential.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Ubiquitination in cancer: mechanisms and therapeutic opportunities.Cancer communications (London, England) · 2025Review
- Basal metabolic rate shapes the development and progression of hepatocellular carcinoma.BMC cancer · 2025Article
- Targeting the MDK/c-Myc complex to overcome temozolomide resistance in glioma.Clinical and translational medicine · 2025Article
- Comprehensive bioinformatics analysis of MEX3 family genes in hepatocellular carcinoma.Scientific reports · 2025Article
- Mesenchymal stem cell-derived exosomes: a novel therapeutic frontier in hematological disorders.Medical oncology (Northwood, London, England) · 2025Review
- TSPYL5-driven G3BP1 nuclear membrane translocation facilitates p53 cytoplasm sequestration via accelerating RanBP2-mediated p53 sumoylation and nuclear export in neuroblastoma.Cell death & disease · 2025Article
- MIAT: A pivotal oncogenic long noncoding RNA tunning the hallmarks of solid malignancies.Translational oncology · 2025Article
- Tuft cells transdifferentiate to neural-like progenitor cells in the progression of pancreatic cancer.Developmental cell · 2025Article
- A CHD8-TRRAP axis facilitates MYC and E2F target gene regulation in human neural stem cells.iScience · 2025Article
- Association Between Recurrence of High-grade Squamous Intraepithelial Lesions of the Uterine Cervix and p16, C-myc and PIK3CA Proteins-A Single-center Retrospective Study.Cell biochemistry and biophysics · 2025Article
- SNORD80-guided 2'-O-methylation stabilizes the lncRNA GAS5 to regulate cellular stress responses.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- DNA replication stress underpins the vulnerability to oxidative phosphorylation inhibition in colorectal cancer.Cell death & disease · 2025Article
- FAT1 functions as an oncogenic driver in triple negative breast cancer through AKT pathway-driven effects on the matrisome.International journal of biological sciences · 2025Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 2 countries.
Yu Chen Feng *School of Biomedical Sciences and Pharmacy, The University of Newcastle, Newcastle, 2308, NSW, Australia.ORCID http://orcid.org/0000-0001-5507-8129
Xiao Ying Liu *Translational Research Institute, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Academy of Medical Science, Zhengzhou University, Zhengzhou, 450053, Henan, China.ORCID http://orcid.org/0000-0003-3450-5683
Liu TengTranslational Research Institute, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Academy of Medical Science, Zhengzhou University, Zhengzhou, 450053, Henan, China.
Qiang JiTranslational Research Institute, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Academy of Medical Science, Zhengzhou University, Zhengzhou, 450053, Henan, China.
Yongyan WuDepartment of Otolaryngology, Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, the first affiliated hospital, Shanxi Medical University, Taiyuan, 030001, Shanxi, China.ORCID http://orcid.org/0000-0003-1669-3860
Jin Ming LiTranslational Research Institute, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Academy of Medical Science, Zhengzhou University, Zhengzhou, 450053, Henan, China.
Wei GaoDepartment of Otolaryngology, Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, the first affiliated hospital, Shanxi Medical University, Taiyuan, 030001, Shanxi, China.ORCID http://orcid.org/0000-0001-7836-2851
Yuan Yuan ZhangSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Newcastle, 2308, NSW, Australia.ORCID http://orcid.org/0000-0001-5851-5128
Ting LaSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Newcastle, 2308, NSW, Australia.
Hessam TabatabaeeSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Newcastle, 2308, NSW, Australia.ORCID http://orcid.org/0000-0001-8912-1746
Xu Guang YanSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Newcastle, 2308, NSW, Australia.ORCID http://orcid.org/0000-0001-5995-8537
M Fairuz B JamaluddinSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Newcastle, 2308, NSW, Australia.ORCID http://orcid.org/0000-0002-7343-9298
Didi ZhangDepartment of Orthopaedics, John Hunter Hospital, Hunter New England Health, Newcastle, 2305, NSW, Australia.
Su Tang GuoDepartment of Molecular Biology, Shanxi Cancer Hospital and Institute, Taiyuan, 030013, Shanxi, China.
Rodney J ScottSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Newcastle, 2308, NSW, Australia.ORCID http://orcid.org/0000-0001-7724-3404
Tao LiuChildren's Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, 2750, NSW, Australia.
Rick F ThorneSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Newcastle, 2308, NSW, Australia.ORCID http://orcid.org/0000-0001-7882-7081
Xu Dong ZhangSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Newcastle, 2308, NSW, Australia. Xu.Zhang@newcastle.edu.au.ORCID http://orcid.org/0000-0001-9457-8003
Lei JinTranslational Research Institute, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Academy of Medical Science, Zhengzhou University, Zhengzhou, 450053, Henan, China. Lei.Jin@newcastle.edu.au.ORCID http://orcid.org/0000-0001-7187-9671
University of Newcastle Australia · AUZhengzhou University · CNShanxi Medical University · CNHenan Provincial People's Hospital · CNJohn Hunter Hospital · AUShanxi Provincial Cancer Hospital · CNUNSW Sydney · AU
Funding
No grant is acknowledged in the PubMed record.
Abstract
The functions of the proto-oncoprotein c-Myc and the tumor suppressor p53 in controlling cell survival and proliferation are inextricably linked as "Yin and Yang" partners in normal cells to maintain tissue homeostasis: c-Myc induces the expression of ARF tumor suppressor (p14
Indexed as
CarcinogenesisCarrier ProteinsCell Line, TumorCell SurvivalGene Expression Regulation, NeoplasticHumansNeoplasmsPromoter Regions, GeneticProtein BindingProto-Oncogene Proteins c-mycRNA, Long NoncodingSumoylationTumor Suppressor Protein p53UbiquitinationCarrier ProteinsMYC protein, humanProto-Oncogene Proteins c-mycRNA, Long NoncodingTP53 protein, humanTRIML2 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.